Compare FEIM & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | OABI |
|---|---|---|
| Founded | 1961 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.9M | 696.4M |
| IPO Year | 1994 | 2021 |
| Metric | FEIM | OABI |
|---|---|---|
| Price | $64.31 | $4.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $95.50 | $8.33 |
| AVG Volume (30 Days) | 265.0K | ★ 1.1M |
| Earning Date | 09-10-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.56 |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $63,227,000.00 | $18,666,000.00 |
| Revenue This Year | $30.80 | $87.73 |
| Revenue Next Year | $26.18 | $25.31 |
| P/E Ratio | $161.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.05 | $1.32 |
| 52 Week High | $89.76 | $5.43 |
| Indicator | FEIM | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 34.47 | 53.41 |
| Support Level | $55.99 | $1.93 |
| Resistance Level | $79.36 | $5.06 |
| Average True Range (ATR) | 3.78 | 0.33 |
| MACD | -2.43 | -0.05 |
| Stochastic Oscillator | 4.38 | 58.33 |
Frequency Electronics Inc is a world leader in precision time and frequency generation technology, which is incorporated into commercial and U.S. Government satellites, Command, Control, Communication, Computer, Intelligence, Surveillance and Reconnaissance, and Electronic Warfare systems. Its technology is used for a wide range of space and non-space applications. The company has two segments FEI-NY, and FEI-Zyfer. Majority of revenue come from FEI-NY which provides precision time, frequency generation and synchronization products and subsystems that are found on-board satellites, in ground-based communication systems and imbedded in mobile platforms operated by the U.S. military.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.